Telephone
61.2.8051.3043
Address
Level 36, Gateway 1 Macquarie Place Sydney, New South Wales (NSW) 2000
Description
Race Oncology Ltd. is a clinical stage biotechnology company, which engages in the discovery and development of a novel approach to cancer treatment and cardio protection. The firm is involved in developing Bisantrene, a small molecule anthracene chemotherapeutic, to address the unmet need of patients across multiple oncology indications, with an initial focus on metastatic breast cancer and acute myeloid leukemia. It is also investigating the impact Bisantrene and new molecules have on the m6A RNA pathway. The company was founded on February 15, 2011 and is headquartered in Sydney, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.64 - 2.09
Trade Value (12mth)
AU$49,312.00
1 week
-2.35%
1 month
18.15%
YTD
95.29%
1 year
89.71%
All time high
4.23
EPS 3 yr Growth
73.60%
EBITDA Margin
N/A
Operating Cashflow
-$10m
Free Cash Flow Return
-43.60%
ROIC
-63.10%
Interest Coverage
N/A
Quick Ratio
9.30
Shares on Issue (Fully Dilluted)
165m
HALO Sector
Healthcare
Next Company Report Date
22-Aug-25
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
05 September 24 |
Notification of cessation of securities - RAC
×
Notification of cessation of securities - RAC |
05 September 24 |
Application for quotation of securities - RAC
×
Application for quotation of securities - RAC |
02 September 24 |
Race Oncology Board Renewal Update
×
Race Oncology Board Renewal Update |
02 September 24 |
Appendix 3Z - Mary Harney
×
Appendix 3Z - Mary Harney |
02 September 24 |
Appendix 3Z - Phillip Lynch
×
Appendix 3Z - Phillip Lynch |
02 September 24 |
Appendix 3X - Dr Daniel Tillett
×
Appendix 3X - Dr Daniel Tillett |
02 September 24 |
Appendix 3X - Dr Serge Scrofani
×
Appendix 3X - Dr Serge Scrofani |
29 August 24 |
Application for quotation of securities - RAC
×
Application for quotation of securities - RAC |
27 August 24 |
Appendix 4E & Annual Report
×
Appendix 4E & Annual Report |
27 August 24 |
Corporate Governance Statement
×
Corporate Governance Statement |
27 August 24 |
Appendix 4G
×
Appendix 4G |
22 August 24 |
Application for quotation of securities - RAC
×
Application for quotation of securities - RAC |
15 August 24 |
Application for quotation of securities - RAC
×
Application for quotation of securities - RAC |
09 August 24 |
Application for quotation of securities - RAC
×
Application for quotation of securities - RAC |
06 August 24 |
Application for quotation of securities - RAC
×
Application for quotation of securities - RAC |
01 August 24 |
Application for quotation of securities - RAC
×
Application for quotation of securities - RAC |
30 July 24 |
Bisantrene Phase 2 AML Trial Successful Concludes
×
Bisantrene Phase 2 AML Trial Successful Concludes |
25 July 24 |
Race to Present at TechKnow July Conference
×
Race to Present at TechKnow July Conference |
25 July 24 |
Application for quotation of securities - RAC
×
Application for quotation of securities - RAC |
23 July 24 |
Quarterly Activity Report and Appendix 4C
×
Quarterly Activity Report and Appendix 4C |
18 July 24 |
Application for quotation of securities - RAC
×
Application for quotation of securities - RAC |
12 July 24 |
Bioshares 18th Biotech Summit Presentation
×
Bioshares 18th Biotech Summit Presentation |
11 July 24 |
Application for quotation of securities - RAC
×
Application for quotation of securities - RAC |
04 July 24 |
Application for quotation of securities - RAC
×
Application for quotation of securities - RAC |
02 July 24 |
Distinguished Oncologist Daniel Von Hoff Joins as Consultant
×
Distinguished Oncologist Daniel Von Hoff Joins as Consultant |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.